Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study by Shuhui You, Die Sang, Fei Xu, Ting Luo, Peng Yuan, Yizhao Xie, Biyun Wang

Get full text

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis by Shuhui You, Shuhui You, Yizhao Xie, Die Sang, Ting Luo, Peng Yuan, Fei Xu, Biyun Wang, Biyun Wang

Get full text

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a r... by Jie Ju, Song‐Lin Gao, Jia‐Yu Wang, Die Sang, Yi‐Kun Kang, Xue Wang, Jian Yue, You Shuai, Yi‐Xin Qi, Peng Yuan

Get full text

Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study by Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Fei Ma, Ying Fan, Peng Yuan, Binghe Xu, Qiao Li

Get full text